Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5028442 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Single dose |
| RO5028442 | DRUG | Single dose |
Inclusion Criteria: * Patients with a diagnosis of Autistic Disorder as defined by DSM-IV, confirmed by the team and supported with the Autistic Diagnostic Observation Schedule (ADOS) * Male adults, 18 to 45 years of age * IQ \> 70 (Wechsler Adult Intelligence Scale-Full scale) * Body mass index (B...
RO5028442 is an investigational small molecule being studied for the treatment of Autistic Disorder. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being developed by Roche Holding AG.
The molecular target of RO5028442 has not been disclosed in available information. The drug is being investigated for its potential effects in patients with Autistic Disorder, but its specific mechanism of action is not publicly detailed.
RO5028442 is being developed by Roche Holding AG, a multinational healthcare company. The company's stock is traded under the ticker RHHBY. The drug is currently in Phase 1 clinical development for Autistic Disorder.
RO5028442 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of Autistic Disorder.
RO5028442 has one completed clinical trial, NCT01474278, titled "A Study of RO5028442 in Adult Male High-Functioning Autistic Patients." This Phase 1 study enrolled 19 participants in the United States and was a randomized, double-blind, placebo-controlled trial.
No alternative names for RO5028442 have been disclosed in available information. The drug is identified solely by its code name RO5028442 and is being developed by Roche Holding AG for Autistic Disorder.